ARTICLE
Keratins comprise a multigenic family of fibrous proteins that form the
cell cytoskeleton; they are made of distinct polypeptides that have been
classified, according to their MW and isoelectric point, as type I (or
acidic or low MW) and type II (or basic or high MW) polypeptides. So far,
about 30 different polypeptides have been recognized [1, 2]; their expression
varies according to the state of differentiation of each individual epithelial
cell. We and others [3] recently observed that the monoclonal antibody
C8/144B, generated against the CD8 molecule of suppressor and cytotoxic
T cells, also reacts with cells of the outer root sheath of hair follicles
around the bulge area, but not with other parts of the hair follicle or
the epidermis. Recent investigations (expression cloning and immunoprecipitation)
showed that this antibody recognizes native (but not denatured) keratin
15 (K15) which seems to be specifically expressed, within human skin,
by hair follicle stem cells located in the bulge [4]. So far K15 has not
been studied extensively in normal and diseased human skin. We therefore
investigated the expression of K15 in a group of cutaneous tumors of known
or alleged follicular origin, in order to assess the usefulness of the
C8/144B antibody in the diagnosis of pilar tumors of the skin.
Material
and methods
Tissue samples
These included biopsy or excision specimens of various epithelial tumors
of known or alleged pilar differentiation (Table
I). The material had been collected in our dermatopathology laboratory,
formalin-fixed and paraffin-embedded.
Immunohistochemistry
4 µm-thick sections placed on electrostatically-treated glass slides
were deparaffinized and rehydrated, then immunolabelled according to a
labelled streptavidin-biotin-peroxidase technique (kit LSAB Dako, Copenhagen,
Denmark), including the following steps: a) antigen retrieval (heating
the sections in citrate buffer with a microwave oven); b) inhibition of
endogenous peroxidase with 1% H2O2 in PBS; c) incubation
of the sections with blocking (non-immune) serum; d) incubation with the
antibody C8/144B (Dako, Copenhagen, Denmark, diluted 1: 10) for 60 min
in moist chambers at room temperature; e) incubation with biotin-conjugated
antiserum to mouse immunoglobulins (10 min); f) incubation with peroxidase-conjugated
streptavidin (10 min). The reaction was revealed with aminoethylcarbazole
as chromogen. Negative controls were performed by omitting the first layer
antibody and they proved consistently negative.
Results (Table
I)
In most specimens normal hair follicles were present that showed cytoplasmic
labelling of basal cells of the outer root sheath in the bulge area (Fig.
1). Several specimens (namely BCC) also contained a variable amount
of lymphocytes that showed membrane staining (corresponding to the CD8
antigen). These structures served as built-in positive controls, and only
specimens with such internal controls were considered. The remaining cutaneous
structures (including basal epidermal keratinocytes and sweat glands)
were unlabelled.
Among hair-follicle tumors, 5/8 trichoepitheliomas showed diffuse cytoplasmic
staining in a proportion of cells varying from 10 to over 75% (Fig.
2). Both basal-cell nevi showed positive staining, but the percentage
of immunoreactive cells was lower. One case each of three trichofolliculomas,
six trichilemmal cysts and 11 trichilemmomas comprised some K15-positive
cells. The remaining cases (including all 7 epidermoid cysts, 11 pilomatricomas
and 17 BCC, most of which showed histologically signs of pilar differentiation)
were unreactive (Fig. 3).
Discussion
The C8/144B monoclonal antibody, raised against the carboxy-terminal
peptide of the CD8 antigen [5], was found to produce cytoplasmic immunostaining
of keratinocytes of the hair follicle bulge. Recently it was shown that
this clone recognizes native keratin 15 (K15) [4]. Although K15 shows
molecular homology with K14, expression cloning and immunoprecipitation
experiments have shown that the C8/144B antibody does not cross-react
with K14 [4]. In order to further clarify this point, we carried out comparative
studies on specimens of normal skin and some K15-positive tumors with
an antibody to K14 (clone LL002) (data not shown). In keeping with previous
results [6], we found K14 expression in basal and suprabasal cells of
the hair follicle and the surface epidermis, whereas C8/144B never produced
such labelling in paraffin-embedded tissue sections. Also in the tumors
studied, the C8/144B and LL002 antibodies yielded different labelling
patterns. These results further confirm the fact that the C8/144B antibody
does not recognize K14.
K15 is a type I (acidic) keratin polypeptide of 50 kDa MW (pI 4.9) that
has so far received little attention in immunohistochemical studies of
normal and diseased skin. Biochemical studies of human [7] and animal
(sheep and mouse) skin [8] have claimed that K15 is expressed at variable
levels in the basal layer of the outer root sheath, in basal epidermal
keratinocytes and sebaceous glands; however in our study and in that of
Lyle et al. [4], K15 was not detected in basal keratinocytes outside
the hair follicle. Within this structure, the distribution of K15 resembles
that of K19, a 40 kDa type I (acidic) polypeptide, also expressed along
the outer root sheath (including cells of the hair bulge) [6]; however
K19 has a broader pattern of expression as compared with K15, since it
is also expressed by more differentiated transient-amplifying cells located
within the lower hair follicle and the epidermis [4, 6]. In keeping with
this fact, K19 has been found to be expressed by a wider array of cutaneous
(adnexal) tumors, including trichoblastomas and BCC [9, 10]. Thus, K15
appears as a more specific immunohistochemical marker of hair follicle
bulge cells.
Our study shows that K15 has a characteristic
expression pattern within pilar tumors. The tumor most frequently expressing
K15 is trichoepithelioma (TE), both of the ordinary and the desmoplastic
type, followed by basal cell nevi. Trichofolliculomas and trichilemmal
tumors only rarely contain K15-positive cells. It seems likely that K15-positive
cells correspond to stem cells of the bulge, suggesting that TE differentiate
(at least partly) toward these cells. By contrast, pilomatricomas do not
express K15, in keeping with their alleged origin from hair-matrix cells
[11]. Epidermal cysts are also devoid of K15-positive cells, in keeping
with their alleged origin from the upper part of the hair follicle (infundibulum).
BCC (of the keratotic type) were also found consistently K15-negative,
and this finding may have histogenetic implications. Indeed, despite the
fact that BCC is the commonest human malignancy, its origin is not yet
known with certainty. On the basis of immunohistochemical studies, namely
using antibodies to various keratin polypeptides, BCC cells have been
found to resemble either bulge [10] or matrix follicular cells [12]. Our
results, showing no expression of K15 in BCC, suggest that this neoplasm
is not related to hair follicle bulge cells.
From a practical point of view, the differential expression of K15 in
TE and (keratotic) BCC may be useful for their differential diagnosis.
Indeed, these tumors may be difficult to separate on histological examination
since both are made of nodular growths of basophilic cells, surrounded
by abundant fibrovascular stroma. The presence of CD34-positive dermal
dendritic cells in the peritumoral stroma [13], the expression of the
bcl-2 oncoprotein [14] and a continuous peritumor staining with the lectin
PNA [15] have been claimed to be features favoring the diagnosis of TE
over BCC, but these findings were subsequently disputed [9, 16, 17]. Our
results suggest that K15 staining may be an additional useful adjunct
for the differentiation between BCC and TE, since K15 expression (even
at low levels) would strongly favor the diagnosis of TE vs BCC.
CONCLUSION The
C8/144B monoclonal antibody, recognizing K15, appears as a convenient new
immunohistochemical tool, since it is commercially-available and can be
used in routinely-processed (paraffin-embedded) tissue specimens. This antigen
should be added to the list of immunohistochemical markers useful for the
study of adnexal skin tumors [18, 19]. REFERENCES
1. Moll R, Franke W, Schiller D, Geiger B, Krepler R. The catalog of
human cytokeratins: patterns of expession in normal epithelia, tumors
and cultured cells. Cell 1982; 31: 11-24.
2. Heid H, Moll R, Franke W. Patterns of expression of trichocytic and
epithelial cytokeratins in mammalian tissues. I. Human and bovine hair
follicles. Differentiation 1988; 37: 137-57.
3. Lyle S, Elder D, Cotsarelis G. A cellular marker for the human hair
follicle bulge identifies hair follicle stem cells (abstr). J Invest
Dermatol 1998; 110: 491.
4. Lyle S, Christofidou-Solomidou M, Liu Y, Elder D, Cotsarelis G. The
C8/144B monoclonal antibody recognizes cytokeratin 15 and defines the
location of human hair follicle stem cells. J Cell Sci 1998; 111:
3179-88.
5. Mason D, Cordell J, Gaulard P, Tse A, Brown M. Immunohistological
detection of human cytotoxic/suppressor T cells using antibodies to a
CD8 peptide sequence. J Clin Pathol 1992; 45: 1084-8.
6. Schirren CG, Burgdorf W, Sander C, Plewig G. Fetal and adult hair
follicle. An immmunohistochemical study of anticytokeratin antibodies
in formalin-fixed and paraffin-embedded tissues. Am J Dermatopathol
1997; 19: 334-40.
7. Eichner R, Kahn M. Differential extraction of keratin subunits and
filaments from normal human epidermis. J Cell Biol 1990; 110: 1149-68.
8. Whitbread L, Powell B. Expression of the intermediate filament keratin
gene, K15, in the basal cell layers of epithelia and the hair follicle.
Exp Cell Res 1998; 244: 448-59.
9. Schirren CG, Rütten A, Kaudewitz P, Diaz C, McClain S, Burgdorf
W. Trichoblastoma and basal cell carcinoma are neoplasms with follicular
differentiation sharing the same profile of cytokeratin intermediate filaments.
Am J Dermatopathol 1997; 19: 341-50.
10. Yoshikawa K, Katagata Y, Kondo S. Biochemical and immunohistochemical
analyses of keratin expression in basal cell carcinoma. J Dermatol
Sci 1998; 17: 15-23.
11. McKee P. Pathology of the Skin. 2nd edition. London: Mosby-Wolfe,
1996.
12. Kore-Eda S, Horiguchi Y, Ueda M, Toda K, Imamura S. Basal cell carcinoma
cells resemble follicular matrix cells rather than follicular bulge cells:
immunohistochemical and ultrasructural comparative studies. Am J Dermatopathol
1998; 20: 362-9.
13. Kirchman T, Prieto V, Smoller B. CD34 staining pattern distinguishes
basal cell epithelioma from trichoepithelioma. Arch Dermatol 1994;
130: 589-92.
14. Smoller B, van de Rijn M, Lebrun D, Warnke R. bcl-2 expression reliably
distinguishes trichoepitheliomas from basal cell carcinomas. Br J Dermatol
1994; 131: 28-31.
15. Vigneswaran N, Haneke E, Peters K. Peanut agglutinin immunohistochemistry
of basal cell carcinoma. J Cutan Pathol 1987; 14: 147-53.
16. Basarab T, Orchard G, Russell-Jones R. The use of immunostaining
for bcl-2 and CD34 and the lectin Peanut Agglutinin in differentiating
between basal cell carcinomas and trichoepitheliomas. Am J Dermatopathol
1998; 20: 448-52.
17. Swanson P, Fitzpatrick M, Ritter J, Glusac E, Wick M. Immunohistologic
differential diagnosis of basal cell carcinoma, squamous cell carcinoma,
and trichoepithelioma in small cutaneous biopsy specimens. J Cutan
Pathol 1998; 25: 153-9.
18. Wick M, Swanson P. Cutaneous Adnexal Tumors. A Guide to Pathologic
Diagnosis. Chicago: ASCP Press, 1991.
19. Kanitakis J. Solid cutaneous tumors. In: Diagnostic Immunohistochemistry
of the Skin. Kanitakis J, Vassileva S, Woodley D, eds. London: Chapman
& Hall Med., 1998: 279-99.
|